Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 18, 2018 - Issue 1
Submit an article Journal homepage
407
Views
6
CrossRef citations to date
0
Altmetric
Original Research

Cost-effectiveness of dolutegravir/abacavir/lamivudine in HIV-1 treatment-Naive (TN) patients in France

Gilles PialouxService des Maladies Infectieuses et Tropicales, AP-HP Hôpital Tenon, PARIS, FranceView further author information
,
Anne-Geneviève MarcelinService de Virologie, Inserm UMR_S 1136, UPMC Univ Paris 06, AP-HP, Hôpitaux Universitaires Pitié Salpêtrière - Charles FoixParis, Paris, FranceView further author information
,
Hélène CawstonReal World Strategy & Analytics, Mapi Group, Nanterre, FranceView further author information
,
Caroline GuilmetReal World Strategy & Analytics, Mapi Group, Nanterre, FranceCorrespondence[email protected]
View further author information
,
Laurent FinkielsztejnMedical affairs, ViiV Healthcare, Rueil-Malmaison, FranceView further author information
,
Audrey LaurisseEU Payer Solution & Access Manager, Viiv Healthcare, Rueil-Malmaison, FranceView further author information
&
Céline AubinHealth Economics and Outcomes Research, Viiv Healthcare, Rueil-Malmaison, FranceView further author information
 show all
Pages 83-91 | Received 07 Apr 2017, Accepted 21 Jul 2017, Published online: 31 Jul 2017

Citations (6)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Brian Godman, Holly McCabe, Trudy D Leong, Debjani Mueller, Antony P. Martin, Iris Hoxha, Julius C. Mwita, Godfrey Mutashambara Rwegerera, Amos Massele, Juliana de Oliveira Costa, Renata Cristina Rezende Macedo do Nascimento, Livia Lovato Pires de Lemos, Konstantin Tachkov, Petya Milushewa, Okwen Patrick, Loveline Lum Niba, Ott Laius, Israel Sefah, Suhaj Abdulsalim, Fatemeh Soleymani, Anastasia N Guantai, Loice Achieng, Margaret Oluka, Arianit Jakupi, Konstantīns Logviss, Mohamed Azmi Hassali, Dan Kibuule, Francis Kalemeera, Mwangana Mubita, Joseph Fadare, Olayinka O. Ogunleye, Zikria Saleem, Shazhad Hussain, Tomasz Bochenek, Ileana Mardare, Alian A. Alrasheedy, Jurij Furst, Dominik Tomek, Vanda Markovic-Pekovic, Enos M. Rampamba, Abubakr Alfadl, Adefolarin A Amu, Zinhle Matsebula, Thuy Nguyen Thi Phuong, Binh Nguyen Thanh, Aubrey Chichonyi Kalungia, Trust Zaranyika, Nyasha Masuka, Ioana D. Olaru, Janney Wale, Ruaraidh Hill, Amanj Kurdi, Angela Timoney, Stephen Campbell & Johanna C. Meyer. (2020) Fixed dose drug combinations – are they pharmacoeconomically sound? Findings and implications especially for lower- and middle-income countries. Expert Review of Pharmacoeconomics & Outcomes Research 20:1, pages 1-26.
Read now

Articles from other publishers (5)

Min Li, Yuxin Cao, Hao Huang, Gang Qin, Minjie Chu, Meiyin Zou & Xun Zhuang. (2023) Cost-effectiveness analysis of antiretroviral drugs for treatment-naive HIV infection in China. BMC Public Health 23:1.
Crossref
Lise Jamieson, Celicia Serenata, Lebogang Makhubele, Simiso Sokhela, Nkuli Mashabane, Godspower Akpomiemie, Leigh F. Johnson, Willem D.F. Venter & Gesine Meyer-Rath. (2021) Cost and cost-effectiveness of dolutegravir-based antiretroviral regimens: an economic evaluation of a clinical trial. AIDS 35:Supplement 2, pages S173-S182.
Crossref
Shuai Chen, Yang Han, Xiao-Jing Song, Yan-ling Li, Ting Zhu, Hong-Zhou Lu, Xiao-Ping Tang, Tong Zhang, Min Zhao, Yun He, Sheng-Hua He, Min Wang, Yong-Zhen Li, Shao-Biao Huang, Yong Li, Jing Liu, Wei Cao & Tai-Sheng Li. (2020) Very high baseline HIV viremia impairs efficacy of non-nucleoside reverse transcriptase inhibitor-based ART: a long-term observation in treatment-naïve patients. Infectious Diseases of Poverty 9:1.
Crossref
Yogesh Suresh Punekar, Na Guo, Gabriel Tremblay, James Piercy, Tim Holbrook & Benjamin Young. (2019) Improving access to antiretrovirals in China: economic analyses of dolutegravir in HIV-1 patients. Cost Effectiveness and Resource Allocation 17:1.
Crossref
Gabriel Tremblay, Vasiliki Chounta, James Piercy, Tim Holbrook, Shan Ashton Garib, Evgeny K. Bukin & Yogesh Suresh Punekar. (2018) Cost-Effectiveness of Dolutegravir as a First-Line Treatment Option in the HIV-1–Infected Treatment-Naive Patients in Russia. Value in Health Regional Issues 16, pages 74-80.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.